Israel

Sol-Gel Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Sol-Gel Technologies Announces FDA Acceptance for Filing of NDA for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea

Lead Product(s): Benzoyl Peroxide

Therapeutic Area: Dermatology Product Name: Epsolay

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 10, 2020

Details:

The NDA filing is based on two positive, identical Phase 3 randomized, double-blind, multicenter, 12-week, clinical trials that evaluated the safety and efficacy of Epsolay compared to vehicle in patients with papulopustular rosacea.

Sol-Gel Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment

Lead Product(s): Benzoyl Peroxide,Tretinoin

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: M. Arkin Dermatology Ltd

Deal Size: $28.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 13, 2020

Details:

The fund will be directed towards the NDA filling of company's drug candidates- Epsolay and Twyneo.

Can-Fite BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020

Lead Product(s): Piclidenoson

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

Interim analysis of the Phase III Comfort trial designed to evaluate the Company’s drug candidate, Piclidenoson, in the treatment of moderate-to-severe plaque psoriasis.

Foamix Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger

Lead Product(s): Serlopitant

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Menlo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger March 09, 2020

Details:

The combined company already has an approved, commercial-stage product, AMZEEQ™, and several late-stage product candidates.

Can-Fite BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results

Lead Product(s): Piclidenoson

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

This year, Can-Fite's reports expand the growing data body demonstrating that both Piclidenoson and Namodenoson have beneficial safety profiles and risk-benefit ratios in over 1,500 patients.

Sol-Gel Technologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks

Lead Product(s): Benzoyl Peroxide

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea. Results pave the way for NDA submission in 2020.

Foamix Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

The Boulder Peptide Society

Participation Not Confirmed

Update your events

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103

Lead Product(s): Minocycline

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 06, 2020

Details:

Both studies demonstrated statistically significant superiority of FMX103 compared with vehicle in both primary endpoints of absolute inflammatory lesion reduction.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Sol-Gel Technologies

Sol-Gel Technologies Announces FDA Acceptance for Filing of NDA for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea

Sol-Gel Technologies

Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment

Can-Fite BioPharma

Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020

Foamix Pharmaceuticals

Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger

Can-Fite BioPharma

Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results

Sol-Gel Technologies

Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay® for Treatment up to 52 Weeks

Foamix Pharmaceuticals

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103